You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePhenelzine
Accession NumberDB00780  (APRD00099)
TypeSmall Molecule
GroupsApproved
DescriptionAn irreversible non-selective inhibitor of monoamine oxidase. May be used to treat major depressive disorder.
Structure
Thumb
Synonyms
Alazine
Fenelzina
Monofen
Nardil
Phenelzin
Phénelzine
Phenelzinum
β-Phenylethylhydrazine
External Identifiers
  • W 1544
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NardilTablet, film coated15 mg/1OralParke Davis Div Of Pfizer Inc1961-06-09Not applicableUs
NardilTablet15 mgOralErfa Canada 2012 Inc1981-12-31Not applicableCanada
Phenelzine SulfateTablet, film coated15 mg/1OralGreenstone LLC1961-06-09Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Phenelzine SulfateTablet15 mg/1OralNovel Laboratories, Inc.2011-02-14Not applicableUs
Phenelzine SulfateTablet15 mg/1OralGAVIS Pharmaceuticals, LLC2010-12-14Not applicableUs
Phenelzine SulfateTablet15 mg/1OralGolden State Medical Supply, Inc.2010-12-14Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
MargylDIM
NardelzinePfizer
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Phenelzine Sulfate
ThumbNot applicableDBSALT000954
Phenelzine Sulphate
ThumbNot applicableDBSALT000955
Categories
UNIIO408N561GF
CAS number51-71-8
WeightAverage: 136.1943
Monoisotopic: 136.100048394
Chemical FormulaC8H12N2
InChI KeyRMUCZJUITONUFY-UHFFFAOYSA-N
InChI
InChI=1S/C8H12N2/c9-10-7-6-8-4-2-1-3-5-8/h1-5,10H,6-7,9H2
IUPAC Name
(2-phenylethyl)hydrazine
SMILES
NNCCC1=CC=CC=C1
Pharmacology
IndicationFor the treatment of major depressive disorder. Has also been used with some success in the management of bulimia nervosa.
Structured Indications
PharmacodynamicsPhenelzine belongs to a class of antidepressants called monoamine oxidase inhibitors (MAOIs). MAO is an enzyme that catalyzes the oxidative deamination of a number of amines, including serotonin, norepinephrine, epinephrine, and dopamine. Two isoforms of MAO, A and B, are found in the body. MAO-A is mainly found within cells located in the periphery and catalyzes the breakdown of serotonin, norepinephrine, epinephrine, dopamine and tyramine. MAO-B acts on phenylethylamine, norepinephrine, epinephrine, dopamine and tyramine, is localized extracellularly and is found predominantly in the brain. While the mechanism of MAOIs is still unclear, it is thought that they act by increasing free serotonin and norepinephrine concentrations and/or by altering the concentrations of other amines in the CNS. It has been postulated that depression is caused by low levels of serotonin and/or norepinephrine and that increasing serotonergic and norepinephrinergic neurotransmission results in relief of depressive symptoms. MAO A inhibition is thought to be more relevant to antidepressant activity than MAO B inhibition. Selective MAO B inhibitors, such as selegiline, have no antidepressant effects. Response to therapy generally occurs 2 - 4 weeks following onset though some patients may not experience symptom relief for up to 8 weeks.
Mechanism of actionAlthough the exact mechanism of action has not been determined, it appears that the irreversible, nonselective inhibition of MAO by phenelzine relieves depressive symptoms by causing an increase in the levels of serotonin, norepinephrine, and dopamine in the neuron.
TargetKindPharmacological actionActionsOrganismUniProt ID
Amine oxidase [flavin-containing] AProteinyes
antagonist
HumanP21397 details
Amine oxidase [flavin-containing] BProteinyes
antagonist
HumanP27338 details
Membrane primary amine oxidaseProteinunknown
inhibitor
HumanQ16853 details
4-aminobutyrate aminotransferase, mitochondrialProteinunknown
inhibitor
HumanP80404 details
Alanine aminotransferase 1Proteinunknown
inhibitor
HumanP24298 details
Alanine aminotransferase 2Proteinunknown
inhibitor
HumanQ8TD30 details
Glutamic acid decarboxylaseProteinunknown
inhibitor
HumanQ9UGI5 details
Related Articles
AbsorptionReadily absorbed after oral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic. Acetylation of phenelzine appears to be a minor metabolic pathway. Beta-phenylethylamine is a metabolite of phenelzine, and there is indirect evidence that phenelzine may also be ring-hydroxylated and N-methylated.

Route of eliminationNARDIL ® is extensively metabolized, primarily by oxidation via monoamine oxidase.
Half life1.2-11.6 hours following single dose administration. Multiple-dose pharmacokinetics have not been studied.
ClearanceNot Available
ToxicitySymptoms of overdose include drowsiness, dizziness, faintness, irritability, hyperactivity, agitation, severe headache, hallucinations, trismus, opisthotonos, convulsions and coma, rapid and irregular pulse, hypertension, hypotension and vascular collapse, precordial pain, respiratory depression and failure, hyperpyrexia, diaphoresis, and cool, clammy skin. Hypertensive crisis may occur with the ingestion of tyramine-rich foods such as cured meats, poultry or fish, aged cheeses, concentrated soy products, tap beer and wine, yeast extracts, broad bean pods and fava beans and sauerkraut.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetaminePhenelzine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetaminePhenelzine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetaminePhenelzine may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetaminePhenelzine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEPhenelzine may increase the hypertensive activities of 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AcarbosePhenelzine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololPhenelzine may increase the hypotensive activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Acetophenazine.Approved
AlbiglutidePhenelzine may increase the hypoglycemic activities of Albiglutide.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Phenelzine.Approved
AlfentanilAlfentanil may increase the serotonergic activities of Phenelzine.Approved, Illicit
AliskirenPhenelzine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Phenelzine.Approved, Investigational
AlogliptinPhenelzine may increase the hypoglycemic activities of Alogliptin.Approved
AlprenololPhenelzine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Phenelzine.Approved
AmbrisentanPhenelzine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Phenelzine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Phenelzine.Approved
AmineptinePhenelzine may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Phenelzine.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Amisulpride.Approved, Investigational
AmitriptylinePhenelzine may increase the serotonergic activities of Amitriptyline.Approved
AmlodipinePhenelzine may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Phenelzine.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Phenelzine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Amperozide.Experimental
AmphetaminePhenelzine may increase the hypertensive activities of Amphetamine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Phenelzine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Phenelzine.Approved
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Phenelzine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Phenelzine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Phenelzine.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Phenelzine.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Asenapine.Approved
AtenololPhenelzine may increase the hypotensive activities of Atenolol.Approved
AtomoxetinePhenelzine may increase the central neurotoxic activities of Atomoxetine.Approved
AtropinePhenelzine may increase the hypertensive activities of Atropine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Azaperone.Vet Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Phenelzine.Approved
BambuterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Bambuterol.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Phenelzine.Experimental
BarbitalBarbital may increase the hypotensive activities of Phenelzine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Phenelzine.Approved
BenazeprilPhenelzine may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazidePhenelzine may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinPhenelzine may increase the hypertensive activities of Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Benperidol.Investigational
BenzphetaminePhenelzine may increase the hypertensive activities of Benzphetamine.Approved, Illicit
BepridilPhenelzine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Phenelzine.Approved
BetaxololPhenelzine may increase the hypotensive activities of Betaxolol.Approved
BethanidinePhenelzine may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Phenelzine is combined with Bezafibrate.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Phenelzine is combined with Bifeprunox.Investigational
BimatoprostPhenelzine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololPhenelzine may increase the hypotensive activities of Bisoprolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Phenelzine.Approved, Investigational
BosentanPhenelzine may increase the hypotensive activities of Bosentan.Approved, Investigational
BretyliumPhenelzine may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Phenelzine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Brimonidine.Approved
BrimonidinePhenelzine may increase the hypotensive activities of Brimonidine.Approved
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Phenelzine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Bromperidol.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Phenelzine.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Phenelzine.Approved, Investigational
BupranololPhenelzine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Phenelzine.Approved, Illicit, Investigational, Vet Approved
BupropionPhenelzine may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Phenelzine.Approved, Investigational
CabergolineThe metabolism of Cabergoline can be decreased when combined with Phenelzine.Approved
CanagliflozinPhenelzine may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanPhenelzine may increase the hypotensive activities of Candesartan.Approved
CandoxatrilPhenelzine may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilPhenelzine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Phenelzine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Phenelzine.Approved
CariprazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Cariprazine.Approved
CaroxazonePhenelzine may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololPhenelzine may increase the hypotensive activities of Carteolol.Approved
CarvedilolPhenelzine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololPhenelzine may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazidePhenelzine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenterminePhenelzine may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamidePhenelzine may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidonePhenelzine may increase the hypotensive activities of Chlorthalidone.Approved
CilazaprilPhenelzine may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Phenelzine.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Phenelzine.Approved
CirazolinePhenelzine may increase the hypertensive activities of Cirazoline.Experimental
CitalopramPhenelzine may increase the serotonergic activities of Citalopram.Approved
ClemastinePhenelzine may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Clenbuterol.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Phenelzine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Phenelzine.Approved, Investigational
ClomipraminePhenelzine may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClonidinePhenelzine may increase the hypotensive activities of Clonidine.Approved
ClozapineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Phenelzine.Approved, Investigational
CryptenaminePhenelzine may increase the hypotensive activities of Cryptenamine.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Cyamemazine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Phenelzine.Approved
CyclothiazidePhenelzine may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadinePhenelzine may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinPhenelzine may increase the hypoglycemic activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Phenelzine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Phenelzine.Investigational
DebrisoquinPhenelzine may increase the hypotensive activities of Debrisoquin.Approved
DeserpidinePhenelzine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Phenelzine.Approved
DesipraminePhenelzine may increase the serotonergic activities of Desipramine.Approved
DesvenlafaxinePhenelzine may increase the serotonergic activities of Desvenlafaxine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Phenelzine.Approved, Vet Approved
DexmethylphenidatePhenelzine may increase the hypertensive activities of Dexmethylphenidate.Approved
DextroamphetaminePhenelzine may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanPhenelzine may increase the serotonergic activities of Dextromethorphan.Approved
DiazoxidePhenelzine may increase the hypotensive activities of Diazoxide.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Phenelzine.Approved
DiethylpropionPhenelzine may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazinePhenelzine may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Phenelzine.Approved
DiltiazemPhenelzine may increase the hypotensive activities of Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Phenelzine.Approved
DipivefrinThe risk or severity of adverse effects can be increased when Phenelzine is combined with Dipivefrin.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Phenelzine.Approved
DisopyramidePhenelzine may increase the hypoglycemic activities of Disopyramide.Approved
DobutamineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Dobutamine.Approved
DolasetronDolasetron may increase the serotonergic activities of Phenelzine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamidePhenelzine may increase the hypotensive activities of Dorzolamide.Approved
DosulepinPhenelzine may increase the serotonergic activities of Dosulepin.Approved
DoxapramPhenelzine may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinPhenelzine may increase the hypotensive activities of Doxazosin.Approved
DoxepinPhenelzine may increase the serotonergic activities of Doxepin.Approved
DoxylaminePhenelzine may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DroperidolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Droperidol.Approved, Vet Approved
DroxidopaThe risk or severity of adverse effects can be increased when Phenelzine is combined with Droxidopa.Approved, Investigational
DulaglutidePhenelzine may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetinePhenelzine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EcopipamThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ecopipam.Investigational
EfonidipinePhenelzine may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Phenelzine.Approved, Investigational
EmpagliflozinPhenelzine may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilPhenelzine may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatPhenelzine may increase the hypotensive activities of Enalaprilat.Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Phenelzine.Approved, Investigational
EphedraThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrinePhenelzine may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Phenelzine.Approved
EpoprostenolPhenelzine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanPhenelzine may increase the hypotensive activities of Eprosartan.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ergonovine.Approved
ErgotaminePhenelzine may increase the hypertensive activities of Ergotamine.Approved
EscitalopramPhenelzine may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmirtazapinePhenelzine may increase the serotonergic activities of Esmirtazapine.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Phenelzine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Phenelzine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Phenelzine.Approved
EtoperidonePhenelzine may increase the serotonergic activities of Etoperidone.Approved
ExenatidePhenelzine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipinePhenelzine may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fenfluramine.Illicit, Withdrawn
FenoldopamPhenelzine may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fenoterol.Approved
FentanylFentanyl may increase the serotonergic activities of Phenelzine.Approved, Illicit, Investigational, Vet Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Phenelzine.Approved
FluoxetinePhenelzine may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fluphenazine.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fluspirilene.Approved
FluvoxaminePhenelzine may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Formoterol.Approved, Investigational
FosinoprilPhenelzine may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Phenelzine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Phenelzine.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Phenelzine.Approved, Vet Approved
GliclazidePhenelzine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepiridePhenelzine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizidePhenelzine may increase the hypoglycemic activities of Glipizide.Approved
GlyburidePhenelzine may increase the hypoglycemic activities of Glyburide.Approved
GranisetronGranisetron may increase the serotonergic activities of Phenelzine.Approved, Investigational
GuanabenzPhenelzine may increase the hypotensive activities of Guanabenz.Approved
GuanadrelPhenelzine may increase the hypotensive activities of Guanadrel.Approved
GuanethidinePhenelzine may increase the hypotensive activities of Guanethidine.Approved
GuanfacinePhenelzine may increase the hypotensive activities of Guanfacine.Approved, Investigational
HaloperidolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Phenelzine.Approved, Vet Approved
HexamethoniumPhenelzine may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Phenelzine.Approved
HydracarbazinePhenelzine may increase the hypertensive activities of Hydracarbazine.Approved
HydralazinePhenelzine may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazidePhenelzine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Hydrocodone.Approved, Illicit
HydroflumethiazidePhenelzine may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Hydromorphone.Approved, Illicit
Hydroxyamphetamine hydrobromidePhenelzine may increase the hypertensive activities of Hydroxyamphetamine hydrobromide.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Phenelzine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Phenelzine.Investigational
ImipraminePhenelzine may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Indacaterol.Approved
IndalpinePhenelzine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamidePhenelzine may increase the hypotensive activities of Indapamide.Approved
IndenololPhenelzine may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminPhenelzine may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartPhenelzine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirPhenelzine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlarginePhenelzine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisinePhenelzine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanPhenelzine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproPhenelzine may increase the hypoglycemic activities of Insulin Lispro.Approved
IproclozidePhenelzine may increase the hypertensive activities of Iproclozide.Withdrawn
IproniazidPhenelzine may increase the hypertensive activities of Iproniazid.Withdrawn
IrbesartanPhenelzine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidPhenelzine may increase the hypertensive activities of Isocarboxazid.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Phenelzine.Approved, Vet Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Phenelzine.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Phenelzine.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Phenelzine.Approved, Withdrawn
IsradipinePhenelzine may increase the hypotensive activities of Isradipine.Approved
KetanserinPhenelzine may increase the hypotensive activities of Ketanserin.Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Phenelzine.Approved, Nutraceutical
LabetalolPhenelzine may increase the hypotensive activities of Labetalol.Approved
LacidipinePhenelzine may increase the hypotensive activities of Lacidipine.Approved
LanreotidePhenelzine may increase the hypoglycemic activities of Lanreotide.Approved
LatanoprostPhenelzine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipinePhenelzine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Phenelzine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Phenelzine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Phenelzine.Approved
LevomilnacipranPhenelzine may increase the serotonergic activities of Levomilnacipran.Approved
LevonordefrinPhenelzine may increase the hypertensive activities of Levonordefrin.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Phenelzine.Approved, Investigational
LinezolidThe risk or severity of adverse effects can be increased when Phenelzine is combined with Linezolid.Approved, Investigational
LiraglutidePhenelzine may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetaminePhenelzine may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilPhenelzine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Phenelzine.Approved
LithiumThe risk or severity of adverse effects can be increased when Phenelzine is combined with Lithium.Approved
LofexidinePhenelzine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LorcaserinThe risk or severity of adverse effects can be increased when Phenelzine is combined with Lorcaserin.Approved
LosartanPhenelzine may increase the hypotensive activities of Losartan.Approved
LoxapineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Loxapine.Approved
Lu AA21004The metabolism of Lu AA21004 can be decreased when combined with Phenelzine.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Lurasidone.Approved
MacitentanPhenelzine may increase the hypotensive activities of Macitentan.Approved
ManidipinePhenelzine may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Phenelzine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Phenelzine.Approved
MebanazinePhenelzine may increase the hypertensive activities of Mebanazine.Withdrawn
MecamylaminePhenelzine may increase the hypotensive activities of Mecamylamine.Approved
MecaserminPhenelzine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Melperone.Approved
MephedronePhenelzine may increase the hypertensive activities of Mephedrone.Investigational
MephenterminePhenelzine may increase the hypertensive activities of Mephentermine.Approved
MequitazinePhenelzine may increase the anticholinergic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Mesoridazine.Approved
MetaraminolPhenelzine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminPhenelzine may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Methadone.Approved
MethamphetaminePhenelzine may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Phenelzine.Approved
MethohexitalMethohexital may increase the hypotensive activities of Phenelzine.Approved
MethotrimeprazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Methotrimeprazine.Approved
MethoxaminePhenelzine may increase the hypertensive activities of Methoxamine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Phenelzine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Phenelzine is combined with Methyldopa.Approved
Methylene bluePhenelzine may increase the serotonergic activities of Methylene blue.Investigational
MethylphenidatePhenelzine may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Phenelzine.Approved
MetipranololPhenelzine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Metoclopramide.Approved, Investigational
MetolazonePhenelzine may increase the hypotensive activities of Metolazone.Approved
MetoprololPhenelzine may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosinePhenelzine may increase the hypotensive activities of Metyrosine.Approved
MianserinPhenelzine may increase the neurotoxic activities of Mianserin.Approved
MibefradilPhenelzine may increase the hypotensive activities of Mibefradil.Withdrawn
MidodrinePhenelzine may increase the hypertensive activities of Midodrine.Approved
MifepristonePhenelzine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolPhenelzine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranPhenelzine may increase the serotonergic activities of Milnacipran.Approved
MinaprinePhenelzine may increase the hypertensive activities of Minaprine.Approved
MinoxidilPhenelzine may increase the hypotensive activities of Minoxidil.Approved
MirtazapinePhenelzine may increase the central neurotoxic activities of Mirtazapine.Approved
MMDAPhenelzine may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Moclobemide.Approved
MoexiprilPhenelzine may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Morphine.Approved, Investigational
MoxonidinePhenelzine may increase the hypotensive activities of Moxonidine.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Phenelzine.Approved, Investigational
NadololPhenelzine may increase the hypotensive activities of Nadolol.Approved
NaftopidilPhenelzine may increase the hypotensive activities of Naftopidil.Investigational
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Phenelzine.Approved, Investigational
NateglinidePhenelzine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololPhenelzine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodonePhenelzine may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Phenelzine.Approved, Investigational
NialamidePhenelzine may increase the hypertensive activities of Nialamide.Withdrawn
NicardipinePhenelzine may increase the hypotensive activities of Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Phenelzine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Phenelzine.Approved
NiguldipinePhenelzine may increase the hypotensive activities of Niguldipine.Experimental
NilvadipinePhenelzine may increase the hypotensive activities of Nilvadipine.Approved
NimodipinePhenelzine may increase the hypotensive activities of Nimodipine.Approved
NisoldipinePhenelzine may increase the hypotensive activities of Nisoldipine.Approved
NitrendipinePhenelzine may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Phenelzine.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Phenelzine.Approved, Investigational
NitroprussidePhenelzine may increase the hypotensive activities of Nitroprusside.Approved
NorepinephrinePhenelzine may increase the hypertensive activities of Norepinephrine.Approved
NortriptylinePhenelzine may increase the serotonergic activities of Nortriptyline.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Phenelzine.Approved
OctamoxinPhenelzine may increase the hypertensive activities of Octamoxin.Withdrawn
OctreotidePhenelzine may increase the hypoglycemic activities of Octreotide.Approved, Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Olanzapine.Approved, Investigational
OlmesartanPhenelzine may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Olodaterol.Approved
OmapatrilatPhenelzine may increase the hypotensive activities of Omapatrilat.Investigational
OndansetronOndansetron may increase the serotonergic activities of Phenelzine.Approved
OpipramolPhenelzine may increase the serotonergic activities of Opipramol.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Orciprenaline.Approved
OsanetantThe risk or severity of adverse effects can be increased when Phenelzine is combined with Osanetant.Investigational
OxprenololPhenelzine may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Phenelzine.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Phenelzine.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Phenelzine.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Phenelzine.Approved
PargylinePhenelzine may increase the hypertensive activities of Pargyline.Approved
ParoxetinePhenelzine may increase the serotonergic activities of Paroxetine.Approved, Investigational
PasireotidePhenelzine may increase the hypoglycemic activities of Pasireotide.Approved
PenbutololPhenelzine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidinePhenelzine may increase the hypoglycemic activities of Pentamidine.Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Phenelzine.Approved, Vet Approved
PentoliniumPhenelzine may increase the hypotensive activities of Pentolinium.Approved
PerazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Perazine.Investigational
PergolideThe metabolism of Pergolide can be decreased when combined with Phenelzine.Approved, Vet Approved, Withdrawn
PerindoprilPhenelzine may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Phenelzine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Perphenazine.Approved
PethidinePhenelzine may increase the serotonergic activities of Pethidine.Approved
PheniprazinePhenelzine may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Phenelzine.Approved
PhenoxybenzaminePhenelzine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenelzine may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhenterminePhenelzine may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolaminePhenelzine may increase the hypotensive activities of Phentolamine.Approved
PhenylephrinePhenelzine may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Phenelzine.Approved, Illicit
PimozideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Pimozide.Approved
PinacidilPhenelzine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololPhenelzine may increase the hypotensive activities of Pindolol.Approved
PioglitazonePhenelzine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Pipotiazine.Approved
PirbuterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Pirbuterol.Approved
PirlindolePhenelzine may increase the hypertensive activities of Pirlindole.Approved
PivhydrazinePhenelzine may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenPhenelzine may increase the anticholinergic activities of Pizotifen.Approved
PolythiazidePhenelzine may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Phenelzine is combined with Pramipexole.Approved, Investigational
PramlintidePhenelzine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinPhenelzine may increase the hypotensive activities of Prazosin.Approved
PrimidonePrimidone may increase the hypotensive activities of Phenelzine.Approved, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Procarbazine.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Procaterol.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Promethazine.Approved
PropericiazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Propericiazine.Approved
PropofolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPhenelzine may increase the hypotensive activities of Propranolol.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Phenelzine is combined with Prothipendyl.Investigational
ProtriptylinePhenelzine may increase the serotonergic activities of Protriptyline.Approved
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Phenelzine.Investigational
PseudoephedrinePhenelzine may increase the hypertensive activities of Pseudoephedrine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Quetiapine.Approved
QuinaprilPhenelzine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuininePhenelzine may increase the hypoglycemic activities of Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Raclopride.Investigational
RamiprilPhenelzine may increase the hypotensive activities of Ramipril.Approved
RasagilinePhenelzine may increase the hypertensive activities of Rasagiline.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Phenelzine.Approved
RemikirenPhenelzine may increase the hypotensive activities of Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Remoxipride.Approved, Withdrawn
RepaglinidePhenelzine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnaminePhenelzine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Reserpine.Approved
RilmenidinePhenelzine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatPhenelzine may increase the hypotensive activities of Riociguat.Approved
RisperidonePhenelzine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ritanserin.Investigational
RitobegronPhenelzine may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ritodrine.Approved
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Phenelzine.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Phenelzine.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ropivacaine.Approved
RosiglitazonePhenelzine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Phenelzine is combined with Sacubitril.Approved
SafrazinePhenelzine may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Salmeterol.Approved
SaprisartanPhenelzine may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinPhenelzine may increase the hypoglycemic activities of Saxagliptin.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Phenelzine.Approved, Vet Approved
SelegilinePhenelzine may increase the hypertensive activities of Selegiline.Approved, Investigational, Vet Approved
SelexipagPhenelzine may increase the hypotensive activities of Selexipag.Approved
SertindoleThe risk or severity of adverse effects can be increased when Phenelzine is combined with Sertindole.Approved, Withdrawn
SertralinePhenelzine may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Sevoflurane.Approved, Vet Approved
SitagliptinPhenelzine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanPhenelzine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Phenelzine is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Phenelzine.Approved
SpiraprilPhenelzine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Phenelzine.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Phenelzine is combined with Streptokinase.Approved
SuccinylcholinePhenelzine may increase the neuromuscular blocking activities of Succinylcholine.Approved
SufentanilSufentanil may increase the serotonergic activities of Phenelzine.Approved, Investigational
SulfadiazinePhenelzine may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazolePhenelzine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazolePhenelzine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Sulpiride.Approved
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Phenelzine.Approved, Investigational
SunitinibPhenelzine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Phenelzine is combined with Tamsulosin.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Phenelzine.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Phenelzine.Approved
TelmisartanPhenelzine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilPhenelzine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Phenelzine.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Terbutaline.Approved
TerlipressinPhenelzine may increase the hypotensive activities of Terlipressin.Approved, Investigational
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Phenelzine.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Phenelzine.Approved
TetryzolinePhenelzine may increase the hypertensive activities of Tetryzoline.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Phenelzine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Phenelzine.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Thiothixene.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Phenelzine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Tiapride.Investigational
TibolonePhenelzine may increase the hypotensive activities of Tibolone.Approved
TicrynafenPhenelzine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololPhenelzine may increase the hypotensive activities of Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Phenelzine.Approved
TolazamidePhenelzine may increase the hypoglycemic activities of Tolazamide.Approved
TolazolinePhenelzine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamidePhenelzine may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Phenelzine.Approved, Withdrawn
ToloxatonePhenelzine may increase the hypertensive activities of Toloxatone.Approved
TorasemidePhenelzine may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Phenelzine.Approved, Investigational
TrandolaprilPhenelzine may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylaminePhenelzine may increase the hypertensive activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Phenelzine.Approved
TravoprostPhenelzine may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Trazodone.Approved, Investigational
TreprostinilPhenelzine may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Phenelzine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Phenelzine.Approved
TrichlormethiazidePhenelzine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Triflupromazine.Approved, Vet Approved
TrimazosinPhenelzine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanPhenelzine may increase the hypotensive activities of Trimethaphan.Approved
TrimipraminePhenelzine may increase the serotonergic activities of Trimipramine.Approved
TropisetronTropisetron may increase the serotonergic activities of Phenelzine.Investigational
UnoprostonePhenelzine may increase the hypotensive activities of Unoprostone.Approved
ValsartanPhenelzine may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxinePhenelzine may increase the serotonergic activities of Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Phenelzine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Phenelzine.Approved
VinpocetinePhenelzine may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Phenelzine.Approved
XylometazolinePhenelzine may increase the hypotensive activities of Xylometazoline.Approved
ZimelidinePhenelzine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ziprasidone.Approved
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Phenelzine.Approved, Investigational
ZotepineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid aged foods (cheese, red wine), pickled foods, cured foods (bacon/ham), chocolate, fava beans, beer, unless approved by your physician.
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid St.John's Wort.
  • Take without regard to meals.
References
Synthesis ReferenceNot Available
General References
  1. Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression]. Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. [PubMed:14574774 ]
  2. Sowa BN, Holt A, Todd KG, Baker GB: Monoamine oxidase inhibitors, their structural analogues, and neuroprotection. Indian J Exp Biol. 2004 Sep;42(9):851-7. [PubMed:15462176 ]
External Links
ATC CodesN06AF03
AHFS Codes
  • 28:16.04.12
PDB Entries
FDA labelDownload (38.9 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9926
Blood Brain Barrier+0.9405
Caco-2 permeable+0.6863
P-glycoprotein substrateNon-substrate0.6728
P-glycoprotein inhibitor INon-inhibitor0.9439
P-glycoprotein inhibitor IINon-inhibitor0.9767
Renal organic cation transporterNon-inhibitor0.6026
CYP450 2C9 substrateNon-substrate0.9166
CYP450 2D6 substrateNon-substrate0.5788
CYP450 3A4 substrateNon-substrate0.8056
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8945
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8995
CYP450 3A4 inhibitorInhibitor0.7961
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7748
Ames testAMES toxic0.6836
CarcinogenicityCarcinogens 0.699
BiodegradationNot ready biodegradable0.8301
Rat acute toxicity2.6507 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7405
hERG inhibition (predictor II)Non-inhibitor0.8735
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Parke davis div warner lambert co
Packagers
Dosage forms
FormRouteStrength
TabletOral15 mg
Tablet, film coatedOral15 mg/1
TabletOral15 mg/1
Prices
Unit descriptionCostUnit
Phenelzine sulfate powder51.0USD g
Nardil 15 mg tablet0.95USD tablet
Nardil 15 mg Tablet0.39USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point< 25 °CPhysProp
boiling point74 °C at 1.00E-01 mm HgPhysProp
water solubility29.1 g/LNot Available
logP1.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility11.1 mg/mLALOGPS
logP1.2ALOGPS
logP1.2ChemAxon
logS-1.1ALOGPS
pKa (Strongest Basic)5.55ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area38.05 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity54.26 m3·mol-1ChemAxon
Polarizability15.8 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0002-9000000000-833e467e14c48ae4f6b3View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenethylamines. These are compounds containing a phenethylamine moiety, which consists of a phenyl group substituted at the second position by an ethan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenethylamines
Direct ParentPhenethylamines
Alternative Parents
Substituents
  • Phenethylamine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Hydrazine derivative
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Chiche F, Le Guillou M, Chetrite G, Lasnier F, Dugail I, Carpene C, Moldes M, Feve B: Antidepressant phenelzine alters differentiation of cultured human and mouse preadipocytes. Mol Pharmacol. 2009 May;75(5):1052-61. doi: 10.1124/mol.108.052563. Epub 2009 Feb 6. [PubMed:19201819 ]
  3. Chenu F, El Mansari M, Blier P: Long-term administration of monoamine oxidase inhibitors alters the firing rate and pattern of dopamine neurons in the ventral tegmental area. Int J Neuropsychopharmacol. 2009 May;12(4):475-85. doi: 10.1017/S1461145708009218. Epub 2008 Aug 13. [PubMed:18700056 ]
  4. Wooters TE, Bardo MT: The monoamine oxidase inhibitor phenelzine enhances the discriminative stimulus effect of nicotine in rats. Behav Pharmacol. 2007 Nov;18(7):601-8. [PubMed:17912044 ]
  5. Volz HP, Gleiter CH: Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging. 1998 Nov;13(5):341-55. [PubMed:9829163 ]
  6. Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression]. Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. [PubMed:14574774 ]
  7. Pickar D, Murphy DL, Cohen RM, Campbell IC, Lipper S: Selective and nonselective monoamine oxidase inhibitors: behavioral disturbances during their administration to depressed patients. Arch Gen Psychiatry. 1982 May;39(5):535-40. [PubMed:7092487 ]
  8. MacKenzie EM, Grant SL, Baker GB, Wood PL: Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition. Neurochem Res. 2008 Mar;33(3):430-6. Epub 2007 Aug 31. [PubMed:17768678 ]
  9. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH: The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf. 2006 Jan;5(1):157-68. [PubMed:16370964 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Chiche F, Le Guillou M, Chetrite G, Lasnier F, Dugail I, Carpene C, Moldes M, Feve B: Antidepressant phenelzine alters differentiation of cultured human and mouse preadipocytes. Mol Pharmacol. 2009 May;75(5):1052-61. doi: 10.1124/mol.108.052563. Epub 2009 Feb 6. [PubMed:19201819 ]
  3. Chenu F, El Mansari M, Blier P: Long-term administration of monoamine oxidase inhibitors alters the firing rate and pattern of dopamine neurons in the ventral tegmental area. Int J Neuropsychopharmacol. 2009 May;12(4):475-85. doi: 10.1017/S1461145708009218. Epub 2008 Aug 13. [PubMed:18700056 ]
  4. Wooters TE, Bardo MT: The monoamine oxidase inhibitor phenelzine enhances the discriminative stimulus effect of nicotine in rats. Behav Pharmacol. 2007 Nov;18(7):601-8. [PubMed:17912044 ]
  5. Volz HP, Gleiter CH: Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging. 1998 Nov;13(5):341-55. [PubMed:9829163 ]
  6. Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression]. Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. [PubMed:14574774 ]
  7. Pickar D, Murphy DL, Cohen RM, Campbell IC, Lipper S: Selective and nonselective monoamine oxidase inhibitors: behavioral disturbances during their administration to depressed patients. Arch Gen Psychiatry. 1982 May;39(5):535-40. [PubMed:7092487 ]
  8. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH: The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf. 2006 Jan;5(1):157-68. [PubMed:16370964 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Tryptamine:oxygen oxidoreductase (deaminating) activity
Specific Function:
Cell adhesion protein that participates in lymphocyte extravasation and recirculation by mediating the binding of lymphocytes to peripheral lymph node vascular endothelial cells in an L-selectin-independent fashion. Has semicarbazide-sensitive (SSAO) monoamine oxidase activity. May play a role in adipogenesis.
Gene Name:
AOC3
Uniprot ID:
Q16853
Molecular Weight:
84621.27 Da
References
  1. Tipnis UR, Tao M, Boor PJ: Purification and characterization of semicarbazide-sensitive amine oxidase from porcine aorta. Cell Mol Biol (Noisy-le-grand). 1992 Aug-Sep;38(5-6):575-84. [PubMed:1483111 ]
  2. Kumar D, Trent MB, Boor PJ: Allylamine and beta-aminopropionitrile induced aortic medial necrosis: mechanisms of synergism. Toxicology. 1998 Feb 6;125(2-3):107-15. [PubMed:9570326 ]
  3. Chiche F, Le Guillou M, Chetrite G, Lasnier F, Dugail I, Carpene C, Moldes M, Feve B: Antidepressant phenelzine alters differentiation of cultured human and mouse preadipocytes. Mol Pharmacol. 2009 May;75(5):1052-61. doi: 10.1124/mol.108.052563. Epub 2009 Feb 6. [PubMed:19201819 ]
  4. Biasi D, Caramaschi P, Pacor ML, Carletto A, Melchiori S, Manzo T, Bambara LM: [Multiple osseous avascular necrosis in a patient with systemic lupus erythematosus with antiphospholipid antibody positivity]. Recenti Prog Med. 1995 Nov;86(11):449-50. [PubMed:8539478 ]
  5. MacKenzie EM, Grant SL, Baker GB, Wood PL: Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition. Neurochem Res. 2008 Mar;33(3):430-6. Epub 2007 Aug 31. [PubMed:17768678 ]
  6. Lizcano JM, Fernandez de Arriba A, Tipton KF, Unzeta M: Inhibition of bovine lung semicarbazide-sensitive amine oxidase (SSAO) by some hydrazine derivatives. Biochem Pharmacol. 1996 Jul 26;52(2):187-95. [PubMed:8694842 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Succinate-semialdehyde dehydrogenase binding
Specific Function:
Catalyzes the conversion of gamma-aminobutyrate and L-beta-aminoisobutyrate to succinate semialdehyde and methylmalonate semialdehyde, respectively. Can also convert delta-aminovalerate and beta-alanine.
Gene Name:
ABAT
Uniprot ID:
P80404
Molecular Weight:
56438.405 Da
References
  1. MacKenzie EM, Grant SL, Baker GB, Wood PL: Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition. Neurochem Res. 2008 Mar;33(3):430-6. Epub 2007 Aug 31. [PubMed:17768678 ]
  2. Tanay VA, Parent MB, Wong JT, Paslawski T, Martin IL, Baker GB: Effects of the antidepressant/antipanic drug phenelzine on alanine and alanine transaminase in rat brain. Cell Mol Neurobiol. 2001 Aug;21(4):325-39. [PubMed:11775064 ]
  3. McKenna KF, McManus DJ, Baker GB, Coutts RT: Chronic administration of the antidepressant phenelzine and its N-acetyl analogue: effects on GABAergic function. J Neural Transm Suppl. 1994;41:115-22. [PubMed:7931216 ]
  4. McManus DJ, Baker GB, Martin IL, Greenshaw AJ, McKenna KF: Effects of the antidepressant/antipanic drug phenelzine on GABA concentrations and GABA-transaminase activity in rat brain. Biochem Pharmacol. 1992 Jun 9;43(11):2486-9. [PubMed:1610412 ]
  5. Todd KG, Baker GB: GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. J Affect Disord. 1995 Dec 13;35(3):125-9. [PubMed:8749840 ]
  6. Todd KG, Baker GB: Neurochemical effects of the monoamine oxidase inhibitor phenelzine on brain GABA and alanine: A comparison with vigabatrin. J Pharm Pharm Sci. 2008 May 16;11(2):14s-21s. [PubMed:19203467 ]
  7. McKenna KF, Baker GB, Coutts RT: N2-acetylphenelzine: effects on rat brain GABA, alanine and biogenic amines. Naunyn Schmiedebergs Arch Pharmacol. 1991 May;343(5):478-82. [PubMed:1881457 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Pyridoxal phosphate binding
Specific Function:
Catalyzes the reversible transamination between alanine and 2-oxoglutarate to form pyruvate and glutamate. Participates in cellular nitrogen metabolism and also in liver gluconeogenesis starting with precursors transported from skeletal muscles (By similarity).
Gene Name:
GPT
Uniprot ID:
P24298
Molecular Weight:
54636.415 Da
References
  1. Todd KG, Baker GB: Neurochemical effects of the monoamine oxidase inhibitor phenelzine on brain GABA and alanine: A comparison with vigabatrin. J Pharm Pharm Sci. 2008 May 16;11(2):14s-21s. [PubMed:19203467 ]
  2. Tanay VA, Parent MB, Wong JT, Paslawski T, Martin IL, Baker GB: Effects of the antidepressant/antipanic drug phenelzine on alanine and alanine transaminase in rat brain. Cell Mol Neurobiol. 2001 Aug;21(4):325-39. [PubMed:11775064 ]
  3. McKenna KF, Baker GB, Coutts RT: N2-acetylphenelzine: effects on rat brain GABA, alanine and biogenic amines. Naunyn Schmiedebergs Arch Pharmacol. 1991 May;343(5):478-82. [PubMed:1881457 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Pyridoxal phosphate binding
Specific Function:
Catalyzes the reversible transamination between alanine and 2-oxoglutarate to form pyruvate and glutamate.
Gene Name:
GPT2
Uniprot ID:
Q8TD30
Molecular Weight:
57903.11 Da
References
  1. Todd KG, Baker GB: Neurochemical effects of the monoamine oxidase inhibitor phenelzine on brain GABA and alanine: A comparison with vigabatrin. J Pharm Pharm Sci. 2008 May 16;11(2):14s-21s. [PubMed:19203467 ]
  2. Tanay VA, Parent MB, Wong JT, Paslawski T, Martin IL, Baker GB: Effects of the antidepressant/antipanic drug phenelzine on alanine and alanine transaminase in rat brain. Cell Mol Neurobiol. 2001 Aug;21(4):325-39. [PubMed:11775064 ]
  3. McKenna KF, Baker GB, Coutts RT: N2-acetylphenelzine: effects on rat brain GABA, alanine and biogenic amines. Naunyn Schmiedebergs Arch Pharmacol. 1991 May;343(5):478-82. [PubMed:1881457 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Pyridoxal phosphate binding
Specific Function:
Not Available
Gene Name:
GAD65
Uniprot ID:
Q9UGI5
Molecular Weight:
47343.69 Da
References
  1. McKenna KF, McManus DJ, Baker GB, Coutts RT: Chronic administration of the antidepressant phenelzine and its N-acetyl analogue: effects on GABAergic function. J Neural Transm Suppl. 1994;41:115-22. [PubMed:7931216 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. MacKenzie EM, Grant SL, Baker GB, Wood PL: Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition. Neurochem Res. 2008 Mar;33(3):430-6. Epub 2007 Aug 31. [PubMed:17768678 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
References
  1. MacKenzie EM, Grant SL, Baker GB, Wood PL: Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition. Neurochem Res. 2008 Mar;33(3):430-6. Epub 2007 Aug 31. [PubMed:17768678 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Runge-Morris M, Feng Y, Zangar RC, Novak RF: Effects of hydrazine, phenelzine, and hydralazine treatment on rat hepatic and renal drug-metabolizing enzyme expression. Drug Metab Dispos. 1996 Jul;24(7):734-7. [PubMed:8818569 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Monooxygenase activity
Specific Function:
Exhibits low testosterone 6-beta-hydroxylase activity.
Gene Name:
CYP3A43
Uniprot ID:
Q9HB55
Molecular Weight:
57669.21 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23